Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Institutional Investors Sentiment Index Worsens in Q2 2019

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo

Sentiment for Oramed Pharmaceuticals Inc (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) institutional sentiment decreased to 1 in Q2 2019. Its down -0.40, from 1.4 in 2019Q1. The ratio turned negative, as 7 institutional investors started new and increased holdings, while 7 sold and reduced their holdings in Oramed Pharmaceuticals Inc. The institutional investors in our partner’s database now have: 808,053 shares, down from 1.04 million shares in 2019Q1. Also, the number of institutional investors holding Oramed Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 5 Increased: 4 New Position: 3.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $53.89 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

The stock decreased 1.59% or $0.05 during the last trading session, reaching $3.1. About 20,799 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 34.17% since October 12, 2018 and is downtrending. It has underperformed by 34.17% the S&P500.

Analysts await Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report earnings on November, 27. They expect $-0.28 earnings per share, down 55.56 % or $0.10 from last year’s $-0.18 per share. After $-0.23 actual earnings per share reported by Oramed Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 21.74 % negative EPS growth.

Sabby Management Llc holds 1.6% of its portfolio in Oramed Pharmaceuticals Inc. for 354,713 shares. Dafna Capital Management Llc owns 16,000 shares or 0.02% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 1,236 shares. The Ontario – Canada-based Bank Of Montreal Can has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 41,186 shares.

Since January 1, 0001, it had 3 insider buys, and 0 insider sales for $272,961 activity.

More notable recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Finance.Yahoo.com which released: “We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully – Yahoo Finance” on September 20, 2019, also Finance.Yahoo.com with their article: “Why You Might Be Interested In Kaiser Aluminum Corporation (NASDAQ:KALU) For Its Upcoming Dividend – Yahoo Finance” published on July 19, 2019, Finance.Yahoo.com published: “Morning News Call – Canada, July 30 – Yahoo Finance” on July 30, 2019. More interesting news about Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were released by: Prnewswire.com and their article: “Oramed to Present at HC Wainwright Global Life Sciences Conference – PRNewswire” published on April 03, 2019 as well as Finance.Yahoo.com‘s news article titled: “Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Insiders Increased Their Holdings – Yahoo Finance” with publication date: August 16, 2019.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.